Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

NOTICE For Investors In OTC: INSD: Update in Lawsuit against Instadose Pharma Corp. announced by Shareholders Foundation

INSD

San Diego, California--(Newsfile Corp. - December 6, 2022) - The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in shares of Instadose Pharma Corp. (OTC: INSD).

Investors, who purchased shares of Instadose Pharma Corp. (OTC: INSD) prior to December 2020 and continue to hold any of those OTC: INSD shares, have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On December 20, 2021, a lawsuit was filed certain investors in OTC: INSD shares against Instadose Pharma Corp. f/k/a Mikrocoze, Inc over alleged violations of securities laws. The plaintiff alleged that the Defendants made false and/or misleading statements and/or failed to disclose that Instadose had performed inadequate due diligence into the Business Combination and/or ignored significant red flags associated with Instadose Canada, that Instadose's internal controls and policies were inadequate to detect and/or prevent impermissible trading activity by control persons of the Company, that the foregoing subjected Instadose to a heightened risk of regulatory scrutiny and enforcement action, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

On August 24, 2022 the plaintiff requested an Entry of Default against the Defendants for failure to appear or respond in a timely manner to the Complaint.

On August 25, the Clerk of the court made an Entry of Default on the Docket as to both Defendants.

Those who purchased shares of Instadose Pharma Corp. (OTC: INSD) should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/146880